Form 4: Arcus Biosciences Chief Medical Officer Reports Stock Transaction

Dimitry Nuyten, Chief Medical Officer of Arcus Biosciences, reports a transaction involving common stock to cover tax obligations related to vested RSUs.

Summary

• On September 15, 2024, Dimitry Nuyten, the Chief Medical Officer of Arcus Biosciences, engaged in a transaction involving the company's common stock.
• The transaction involved the 'net settlement' of 5,385 shares to cover tax withholding obligations related to the vesting and settlement of previously granted Restricted Stock Units (RSUs).
• The shares were disposed of at a price of $17.95.
• Following the transaction, Nuyten directly owns 94,933 shares of Arcus Biosciences common stock, which includes 1,123 shares purchased through the Employee Stock Purchase Plan on May 31, 2024.

Sentiment

Score: 7

Explanation: The document reflects a routine transaction related to executive compensation and tax obligations. It doesn't indicate any significant positive or negative developments for the company, hence a neutral to slightly positive sentiment.

Industry Context

This Form 4 filing is a routine disclosure required by the SEC when a company insider, like the Chief Medical Officer, engages in transactions involving the company's stock. It provides transparency to the market regarding insider activity.

Comparison to Industry Standards

• Form 4 filings are standard practice for publicly traded companies and their insiders, ensuring compliance with SEC regulations.
• The 'net settlement' of RSUs for tax obligations is a common practice among executives at publicly traded companies.

Stakeholder Impact

• The transaction has a minimal direct impact on stakeholders, as it is a routine adjustment of the executive's stock holdings to cover tax obligations.

Key Dates